Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum ferritin as a prognostic biomarker in CAR-T therapy for multiple myeloma: A meta-analysis

28 Mar 2025

Abstract excerpt

Serum ferritin, a marker of systemic inflammation and iron metabolism, has been implicated in the outcomes of patients with relapsed/refractory multiple myeloma (R/R MM). However, its prognostic significance in R/R MM patients undergoing chimeric antigen receptor-modified T-cell (CAR-T) therapy remains unclear. This meta-analysis aimed to evaluate the association between pre-infusion serum ferritin levels and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Iron Metabolism and Disorders
Share to Signaling Pathways in Disease

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40198890
DOI: 10.17305/bb.2025.12129

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serum ferritin as a prognostic biomarker in CAR-T therapy for multiple myeloma: A meta-analysisPMID 40198890Read ↗

Integrated assessment of the clinical and biological value of ferroptosis-related genes in multiple myelomaSemantic proximity Read ↗

Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained responseSemantic proximity Read ↗

Haematopoietic Score for the Prognostic Evaluation of Multiple Myeloma Patients Undergoing First-line Treatment With a Bortezomib-based RegimenSemantic proximity Read ↗

Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma PatientsSemantic proximity Read ↗

Impact of Daratumumab in Transplant Eligible/Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Meta-Analysis of Phase- III TrialsSemantic proximity Read ↗

Outcomes of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma by Race: A Multicenter Real-World StudySemantic proximity Read ↗

FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation–Induced Mitochondrial Oxidative StressSemantic proximity Read ↗

Relapse prediction in multiple myeloma patients treated with isatuximab, carfilzomib, and dexamethasoneSemantic proximity Read ↗

A phase I study of C-CAR088, a novel humanized anti-BCMA CAR T cell therapy in relapsed/refractory multiple myelomaSemantic proximity Read ↗

The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status.Semantic proximity Read ↗

Multiple myeloma: patient outcomes in real-world practice.Semantic proximity Read ↗

Prognostic significance of advanced lung cancer inflammation index (ALI) in multiple myeloma patients – a retrospective studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.